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Abstract
Background: Limited data are available regarding the use of nab-paclitaxel in older patients with breast cancer. A
weekly schedule is recommended, but there is a paucity of evidence regarding the optimal dose. We evaluated the
efficacy of two different doses of weekly nab-paclitaxel, with a specific focus on their corresponding impact on
patient function, in order to address the lack of data specifically relating to the older population.
Methods: EFFECT is an open-label, phase II trial wherein 160 women with advanced breast cancer aged ≥ 65 years
were enrolled from 15 institutions within Italy. Patients were randomly assigned 1:1 to receive nab-paclitaxel 100mg/
m2 (arm A) or 125mg/m2 (arm B) on days 1, 8, and 15 on a 28-day cycle, as first-line treatment for advanced disease.
The primary endpoint was event-free survival (EFS), wherein an event was defined as disease progression (PD),
functional decline (FD), or death. In each arm, the null hypothesis that the median EFS would be ≤ 7months was
tested against a one-sided alternative according to the Brookmeyer Crowley test. Secondary endpoints included
objective response rate (ORR), clinical benefit rate (CBR), progression-free survival (PFS), overall survival (OS), and safety.
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Results: After a median follow-up of 32.6 months, 140 events were observed in 158 evaluable patients. Median EFS
was 8.2 months (90% CI, 5.9–8.9; p = 0.188) in arm A vs 8.3 months (90% CI, 6.2–9.7, p = 0.078) in arm B. Progression-free
survival, overall survival, and response rates were similar in both groups. A higher percentage of dose reductions and
discontinuations due to adverse events (AEs) was noted in arm B. The most frequently reported non-haematological
AEs were fatigue (grade [G] 2–3 toxicity occurrence in arm A vs B, 43% and 51%, respectively) and peripheral
neuropathy (G2–3 arm A vs B, 19% and 38%, respectively).
Conclusion: Pre-specified outcomes were similar in both treatment arms. However, 100 mg/m2 was significantly better
tolerated with fewer neurotoxicity-related events, representing a more feasible dose to be recommended for older
patients with advanced disease.
Trial registration: EudraCT, 2012-002707-18. Registered on June 4, 2012. NIH ClinicalTrials.gov, NCT02783222.
Retrospectively registered on May 26, 2016.
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Background
Older patients are at higher risk of chemotherapy-
related toxicities in comparison with younger adults [1].
Weekly solvent-based taxanes, such as paclitaxel and do-
cetaxel, are amongst the recommended agents to treat
older patients with advanced breast cancer (ABC) [2].
However, close monitoring is required given that
treatment-induced side effects, particularly neurotoxicity
and fatigue, place older patients at risk of subsequent
functional decline (FD) [3–7]. Nanoparticle albumin-
bound paclitaxel (nab-paclitaxel) does not require ster-
oid premedication and is associated with a lower rate of
hypersensitivity reactions [8–10], thus representing an
efficacious and safe alternative to solvent-based taxanes.
Additionally, recovery from nab-paclitaxel-induced
neurotoxicity is reputedly shorter than with solvent-
based taxanes [8, 9], which may subsequently produce a
reduction in negative functional impact. Limited data
exist regarding the use of nab-paclitaxel in elderly pa-
tients, and uncertainty still prevails regarding the ideal
dose to be used in this population. A previous post hoc
analysis of two studies investigated the safety and effi-
cacy of q1w and q3w nab-paclitaxel compared with q3w
solvent-based paclitaxel and docetaxel in older patients
with ABC [11]. Two doses of weekly nab-paclitaxel (150
mg/m2 and 100 mg/m2, on days 1, 8, and 15 on a 28-
day cycle) were evaluated. Nab-paclitaxel was found to
be safer and more efficacious when administered weekly.
However, these conclusions were limited by way of a
small studied group: only 24 patients aged ≥ 65 years
were treated with weekly nab-paclitaxel. Additionally,
the reported 20% incidence of grade 3 sensory neur-
opathy was concerning.
The EFFECT trial aimed to identify the optimal weekly
dose of nab-paclitaxel that could be effectively used in
older patients with ABC, whilst also integrating geriatric
assessment tools to evaluate the impact of treatment on
function.
Methods
Study design and conduct
EFFECT (EudraCT 2012-002707, ClinicalTrials.gov iden-
tifier: NCT02783222) is an open-label, randomized,
phase II study evaluating two doses of weekly nab-
paclitaxel as the first-line treatment in older women with
ABC. Patients were recruited across 15 cancer centres in
Italy, with prospective approval of the protocol by local
independent ethics committees at each site. Written in-
formed consent was obtained from all patients.
Patients and treatments
Eligible patients were female aged ≥ 65 years with patho-
logically confirmed ABC of any hormone receptor (HR)
and HER2 status, and a history of no prior lines of treat-
ment in the advanced setting. In line with the absence of
inclusion of anti-HER2 agents in the trial protocol,
women with HER2-positive disease were required to
have contraindications to their administration. Add-
itional inclusion criteria were Eastern Cooperative On-
cology Group (ECOG) performance status 0–2, the
presence of measurable or evaluable disease according to
the Response Evaluation Criteria in Solid Tumors ver-
sion 1.1 (RECIST v1.1), adequate organ function, and an
absence of active/symptomatic central nervous system
metastases and/or grade ≤ 1 peripheral neuropathy.
Using an interactive web response system (IWRS) and
the minimization algorithm, patients were centrally ran-
domized 1:1 to receive nab-paclitaxel 100mg/m2 (arm
A) or 125 mg/m2 (arm B) on days 1, 8, and 15 on a 28-
day cycle. Patients were stratified according to age (65–
74 vs ≥ 75 years), concomitant diabetes (yes/no), instru-
mental activity of daily living (IADL) impairment (yes/
no), presence of any grade 3–4 illness according to the
Cumulative Illness Rating Scale-Geriatric (CIRS-G) score
(yes/no), measurable vs evaluable disease, treating
centre, and prior exposure to taxanes (yes/no).
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Dose modifications for specific treatment-emergent
toxicities were mandated by the protocol. Patients con-
tinued on trial-assigned treatment until the point of FD,
unacceptable toxicity, consent withdrawal, disease pro-
gression (PD), or death, or at the discretion of the treat-
ing physician.
Study endpoints
The primary study endpoint was event-free survival
(EFS), wherein an “event” was either FD, PD, or death.
FD was defined as a decrease of at least one point from
baseline values of activity of daily living (ADL) and/or
instrumental activity of daily living (IADL) considered
by the investigator to be treatment-related and con-
firmed at subsequent cycle. Secondary endpoints in-
cluded objective response rate (ORR), clinical benefit
rate (CBR), PFS, overall survival (OS), and safety. ORR
was defined by the percentage sum of complete re-
sponses (CR) and partial responses (PR). CBR was calcu-
lated by combining CR, PR, and stable disease (SD).
ORRs and CBRs were determined only in patients with
measurable disease. The calculation of all time-to-event
intervals started from the date of randomization. All ser-
ious and non-serious adverse events (AEs) were graded
according to the Common Terminology Criteria for Ad-
verse Events (CTCAE) version 4.03. Both events related
and unrelated to the study treatment were captured.
Assessments
Tumours were evaluated according to RECIST v1.1
within 28 days before randomization and then every 12
weeks until PD. The presence of comorbidities and func-
tional impairments was assessed at baseline using CIRS-
G [12], ADL [13], and IADL [14] instruments. ADLs and
IADLs were also re-evaluated on day 1 of each cycle.
AEs were recorded and graded according to CTCAE ver-
sion 4.03 and were evaluated by the investigator at every
patient visit from baseline until up to 30 days after dis-
continuation of trial treatment.
Statistical analysis
Efficacy analyses were performed on the modified
intention-to-treat population, which included all ran-
domly assigned patients who received at least one dose
of the study drug. In each arm, the null hypothesis that
the median EFS would be ≤ 7 months was tested against
a one-sided alternative according to the Brookmeyer
Crowley test [15]. It was estimated that with the enrol-
ment of 144 patients (72 in each arm), every hypothesis
test would have a type I error rate of 5% and a power of
90% when the true median EFS was ≥ 12months. The
distributions of all studied patients according to demo-
graphic, clinical, and biologic characteristics and cat-
egorical outcomes were summarized as frequencies and
percentage. Continuous variables were reported as me-
dian and range of variation. The median period of
follow-up and its interquartile range were calculated for
the entire study cohort according to the reverse Kaplan-
Meier method. Distributions of EFS, PFS, and OS were
estimated using the Kaplan-Meier product-limit method.
According to the study design, no formal statistical com-
parisons between the results observed in the two treat-
ment arms were planned or performed. The SAS
software version 9.2 (SAS Institute, Cary, NC) was used
for the statistical analysis.
During data cleaning, it was observed that some pa-
tients had two consecutive reports of G2/3 neurotoxicity
or fatigue (which, by CTCAE definition, imply functional
impairment of ADLs or IADLs) who were not also re-
ported as having FD. Accordingly, a central review was
undertaken. For reports of neurotoxicity, FD was con-
firmed and recorded in the setting of two consecutive
reports of grade 2 or 3 episodes. In the setting of two
consecutive reports of grade 2 or 3 fatigue, the respon-
sible investigator was contacted, and FD was declared/
confirmed only when fatigue was deemed to be
treatment-related. The primary study endpoint is subse-
quently reported both by the investigator and by a cen-
tral review.
As there is an ongoing and unresolved discussion re-
garding which age should be used to define “elderly” pa-
tients, an unplanned subgroup analysis was also
conducted to evaluate major treatment outcomes in pa-
tients aged ≥ 75 years.
Results
Between January 2013 and September 2016, 160 patients
were accrued and randomized in a 1:1 fashion. Overall,
79 patients per arm were evaluable for efficacy and
safety analyses (see CONSORT diagram: Fig. 1). The
baseline demographics are summarized in Table 1. The
median age was 72 years in arm A and 73 years in arm
B. Overall, approximately 70% were aged ≥ 70 years and
> 40% were ≥ 75 years. The majority of patients had ex-
cellent baseline functional status and well-controlled
comorbidities.
Treatment exposure
Overall in both arms, patients received a median of 6 cy-
cles of nab-paclitaxel. In patients aged 75 and over, those
in arm A completed a median of 6 cycles, with a median
of 5 cycles completed by those assigned to arm B
(Table 2). Dose delays were reported in 21% of cycles
undertaken in arm A and in 23% of cycles in arm B.
More than 70% of patients had dose reductions overall—
however, a higher percentage of dose reductions per
cycle was noted in arm B (39% vs 58%) (Table 2). The
main reasons for treatment discontinuations were (arm
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A vs B) PD (53% vs 30%), clinical decision (20% vs 28%),
AEs (14% vs 28%), patient choice (9% vs 4%), and FD
(2.5% vs 5%).
Efficacy
At a median follow-up of 32.6 months (interquartile
range, 23.6–41.6), 140 events were observed. The major-
ity of reported events—over 75% in each arm—consisted
of PD, with on average only 7% of patients overall ex-
periencing FD (Table 3). The median EFS was 8.2 (90%
confidence interval (CI) 5.9–8.9; Brookmeyer-Crowley
like test p = 0.188) and 8.3 (90% CI 6.2–9.7;
Brookmeyer-Crowley like test p = 0.078) months for
arms A and B, respectively (Fig. 2a). At the central re-
view, FD was identified in 17% of patients on average
(Table 3), with a consequent comparative reduction in
the median EFS by 2 months in both arms (median EFS
6.2 months vs 6.4 months for arms A and B, respectively)
(Fig. 2b). Efficacy outcomes are reported in Table 4.
In patients with measurable disease at baseline (n =
125), the ORR was 40% in arm A and 42% in arm B,
with a CBR of 80% and 69%, respectively. In those pa-
tients who discontinued nab-paclitaxel in the absence of
PD, 27% (n = 21) in arm A and 34% (n = 27) in arm B re-
ceived a subsequent line of therapy. The median OS in
arm A was 22.4 months (95% CI 17.0–35.6) and 20.7
months (95% CI 16.8–28.6) in arm B. The main cause of
death in both arms was PD (arm A, n = 48 [61%]; arm B,
n = 45 [57%]).
No difference in the distribution of events was ob-
served within the subgroup of patients aged ≥ 75 years
(Table 3). In this group, the median EFS was 8.3 months
(90% CI 5.7–8.9) in arm A and 8.2 months (90% CI 3.5–
10.9) in arm B. Similar outcomes were observed when
EFS was evaluated according to age subgroup (data not
shown). The median PFS was 8.3 months (95% CI 5.9–
10.5) for arm A and 8.8 months (95% CI 7.4–10.3) for
arm B.
Safety
AEs are reported in Table 5 and are consistent with the
known safety profile of nab-paclitaxel in the general
population. Myelotoxicity was moderate: one patient in
arm A (1%) and three (4%) in arm B experienced G4
neutropenia. G3 febrile neutropaenia was reported in
one (1%) and two patients (2.5%) in arms A and B, re-
spectively. The most frequently reported non-
haematological AEs were fatigue and peripheral neur-
opathy. In arm B, G2/3 neurotoxicity occurred more fre-
quently (38% vs 19% in arm A) and with a shorter
median time to onset than arm A. In arm A, G2 neuro-
toxicity was reported after a median of 6.5 cycles (range,
2–11), with G3 reported after a median of 6 cycles
(range, 3–9). In contrast, G2 neurotoxicity was reported
Fig. 1 CONSORT diagram illustrating the disposition to treatment arms, plus reasons for discontinuing treatment on trial
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Table 1 Baseline characteristics of the ITT population, by treatment arm and age. Reported as n (%) unless otherwise indicated
Characteristics Arm A, 100 mg/m2 Arm B, 125 mg/m2
Overall (N = 79) Patients aged 75+ (N = 33) Overall (N = 79) Patients aged 75+ (N = 33)
Median age in years (range) 72 (65–84) 80 (75–84) 73 (65–88) 77 (75–88)
Age
65–69 28 (35) – 21 (27) –
75+ 33 (42) 33 (100) 33 (42) 33 (100)
ECOG PS
0 51 (65) 20 (61) 43 (54) 19 (58)
1 19 (24) 9 (27) 32 (41) 13 (40)
2 9 (11) 4 (12) 4 (5) 1 (3)
ADL scores
Impaired [range] 14 (18) [5/6–4/6] 6 (18) [5/6–5/6] 20 (25) [5/6–1/6] 8 (24) [5/6–1/6]
Missing data 2 (2) 2 (2) 0 0
IADL scores
Impaired [range] 20 (25) [7/8–2/8] 9 (3) [7/8–4/8] 20 (25) [7/8–2/8] 8 (24) [7/8–3/8]
Missing data 2 (2) 1 (3) 0 0
Comorbidities
Any grades 3–4 8 (10) 6 (18) 10 (13) 3 (9)
Diabetes mellitus 9 (11) 6 (18) 11 (14) 4 (12)
HR status
ER− and PgR− 9 (11) 5 (15) 8 (10) 4 (12)
ER+ and/or PgR+ 68 (86) 28 (85) 67 (85) 28 (85)
Missing data 2 (3) 0 4 (5) 1 (3)
HER2 status
Positive 2 (3) 1 (3) 0 0
Missing data 5 (6) 2 (6) 10 (13) 4 (12)
Prior taxane use 11 (14) 3 (9) 10 (13) 1 (3)
Measurable disease 60 (76) 22 (67) 65 (82) 28 (85)
Visceral disease 56 (71) 22 (67) 55 (69) 25 (76)
ADL activities of daily living, ECOG PS Eastern Cooperative Oncology Group Performance Status, IADL instrumental ADL, + positive, − negative
Table 2 Treatment exposure, described by randomized arm, as well as within the subgroup aged ≥ 75. Reported as n (%) unless
otherwise stated
Regimen received Arm A, 100 mg/m2 Arm B, 125 mg/m2
All (N = 79) Pts aged 75+ (N = 33) All (N = 79) Pts aged 75+ (N = 33)
Total n of cycles 594 214 443 180
Median n cycles (range) 6 (1–28) 6 (1–19) 6 (1–22) 5 (1–11)
Dose delays
N of patients 52 (66) 19 (58) 50 (63) 18 (55)
N of cycles 127 (21) 43 (20) 100 (23) 35 (19)
Dose reductions
N of patients 57 (72) 22 (68) 63 (80) 23 (70)
N of cycles 234 (39) 78 (36) 257 (58) 101 (56)
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in arm B after a median of 5 cycles (range, 1–11), with
G3 reported after a median of 4.5 cycles (range, 3–8). Se-
vere AEs were reported in ten patients (13%) in each
arm. Treatment-related toxicity was reported as the
cause of death in three patients: one patient in arm A
died due to acute renal failure secondary to diarrhoea; in
arm B, one patient died from complications of severe
diarrhoea and another from septic shock secondary to
Clostridium difficile infection after a single dose of
weekly nab-paclitaxel, on a background of long-term use
of corticosteroids and proton pump inhibitors (PPI).
AEs in the patient subgroup aged ≥ 75 years are re-
ported in Additional File 1: Table S1. Of note, two out
of the three grade 5 toxicities were registered in this age
group. The incidence of grade 2–3 fatigue and neurotox-
icity was positively correlated to age in patients treated
in arm B, but not observed in arm A (Additional File 2:
Table S2).
Discussion
EFFECT was designed to prospectively identify a dose of
nab-paclitaxel that might be safely and efficaciously ad-
ministered weekly to older women with ABC. Based on
the two weekly doses previously evaluated by Gradishar
et al. [9] and later explored in a post hoc analysis which
concentrated specifically on the older population [11],
150 mg/m2 was not explored as it was considered too
toxic for older patients. The studied doses of 100 and
125 mg/m2 were chosen based on previous results of a
phase II study evaluating these two doses in patients
with ABC heavily pretreated with taxanes, which showed
weekly nab-paclitaxel 100 mg/m2 (n = 75) had similar
antitumour activity and more favourable safety profile
than 125 mg/m2 (n = 106) [16]. Due to the linear
pharmacokinetics of nab-paclitaxel, we considered it
worthy to investigate both doses in the first-line setting.
Our study showed that the administration of both
doses of nab-paclitaxel was feasible, with a comparable
median number of delivered cycles in the two arms, but
a higher percentage of dose-reduced cycles, and higher
rates of treatment discontinuation due to AEs observed
in arm B. The two weekly doses of nab-paclitaxel were
equally effective and were associated with a similar inci-
dence of FD, noting that the rate of FD increased on the
unplanned central review. However, the lower incidence
of neurotoxicity observed in arm A makes 100 mg/m2 a
more feasible dose in older patients with ABC.
The incidence of neurotoxicity and fatigue are integral
concerns related to the administration of taxanes. As
maintenance of functional status is fundamental to ef-
fective care of the elderly, loss of function was included
in the EFS evaluation in this study. As such, EFFECT
specifically set an elderly-oriented primary endpoint,
wherein EFS was calculated based on the occurrence of
an event (PD, FD, or death). Central review of data re-
vealed a higher rate of FD than what was initially re-
ported by the investigators, highlighting that FD is
commonly under-reported. The explanation for this may
be attributed to a lack of familiarity in evaluating FD in
clinical trials, as well as FD being a phenomenon that is
perhaps under-appreciated in the clinical setting as a
whole. It should be noted that due to the restrictive def-
inition set for FD by the study, the increased observation
of grade 2–3 fatigue and neurotoxicity reported in arm
B did not translate into a higher incidence of FD be-
tween the two treatment arms.
As expected, fatigue and peripheral neuropathy were
the most frequent non-haematological AEs in both arms.
Notably, in arm B, the incidence of grade 2–3 neur-
opathy was double than that of arm A (19% vs 38%).
Contrastingly, at 100mg/m2, the incidence of grade 2
and 3 neurotoxicity was 15% and 4%, respectively. These
Table 3 Primary endpoint-related events in the overall population and in patients aged 75 years and older. Reported as N (%) unless
otherwise indicated
Event Arm A, 100 mg/m2 Arm B, 125 mg/m2
All (N = 79) Pts aged 75+ (N = 33) All (N = 79) Pts aged 75+ (N = 33)
Investigator reported
Pts with reported event 69 (87) 31 (94) 71 (90) 29 (88)
PD 61 (77) 28 (85) 60 (76) 23 (70)
FD 4 (5) 1 (3) 7 (9) 5 (13)
Death 4 (5) 2 (6) 4 (5) 1 (3)
Central review
Pts with reported event 72 (91) 32 (97) 74 (94) 30 (91)
PD 56 (71) 25 (76) 55 (70) 23 (70)
FD 13 (16) 6 (18) 14 (18) 5 (15)
Death 3 (4) 1 (3) 5 (6) 2 (6)
FD functional decline, PD disease progression, Pts patients
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data are comparable with those reported by Gradishar
et al. in an unselected population [9, 10], and equate
favourably with those reported by Aapro et al. in pa-
tients aged ≥ 65 years, treated at the same dose of weekly
nab-paclitaxel (21% grade 3, grade 2 not reported) [11].
In EFFECT, three deaths were reported as the result of
AEs. Diarrhoea was associated with the cause of death in
all three cases, wherein patients experienced secondary
severe dehydration, end-stage renal failure, and septic
shock. Chemotherapy-associated diarrhoea represents a
significant event which requires close monitoring and
aggressive management in older patients, who are at the
highest risk of developing severe and fatal complications
from associated dehydration, renal insufficiency, electro-
lyte imbalance, or infection [17, 18]. Age and recent
antibiotic exposure are well-recognized risk factors for
Fig. 2 Kaplan-Meier analysis of event-free survival by treatment arm: investigator reported (a) and at central review (b)
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the development of Clostridium difficile infection, as
well as the use of PPIs [19] and chemotherapy [20]. This
may suggest that the concomitant use of PPIs with
chemotherapy be made selectively and cautiously in
older patients.
EFFECT evaluated weekly nab-paclitaxel specifically in
patients aged ≥ 65 years, in order to address this popula-
tion’s under-representation in previous clinical trials.
However, a representative subgroup of patients aged ≥
75 years (n = 66) allowed the evaluation of this agent in a
strictly defined “older” population. Advanced age did not
affect treatment feasibility and efficacy but was
associated with a higher incidence of both neurotoxicity
and fatigue with the 125 mg/m2 dose. Notably, two of
the three reported deaths occurred in this age subgroup,
suggesting a need for closer monitoring of AEs in this
potentially less resilient population. The limitations of
the unplanned subgroup analysis of patients aged 75 and
over are acknowledged, highlighting the need to conduct
prospective trials with adequate power to analyse this
particular group of patients. Since the conception and
completion of EFFECT, data has been published from a
small phase II cohort study (N = 40) in patients aged 65
and older receiving 100 mg of nab-paclitaxel on days 1,
Table 4 Efficacy outcomes, reported by arm
Event Arm A, 100 mg/m2 (n = 79) Arm B, 125 mg/m2 (n = 79)








Median PFS, mos (95% CI) 8.3 (5.9–10.5) 8.8 (7.4–10.3)
Median OS, mos (95% CI) 22.4 (17.0–35.6) 20.7 (16.8–28.6)
Best overall response*, n (%) n = 60 n = 65
CR 4 (7) 1 (2)
PR 20 (33) 26 (40)
SD 24 (40) 18 (28)
PD 9 (15) 14 (21)
NE 3 (5) 6 (9)
CI confidence interval, CR complete response, EFS event-free survival, mos months, NE not evaluable, OS overall survival, PFS progression-free survival, PD
progressive disease, PR partial response, SD stable disease
#Based on central review
*Patients with measurable disease
Table 5 Adverse events reported in ≥ 20% of patients if grade 2 or if grades 3–4 occurring at any frequency
Adverse event, n (%) Arm A, 100 mg/m2 (n = 79) Arm B, 125 mg/m2 (n = 79)
All Grade 2 Grade 3 Grade 4 All Grade 2 Grade 3 Grade 4
Anaemia 67 (85) 26 (33) 2 (2.5) – 66 (83.5) 29 (37) – –
Leucopaenia 47 (59) 20 (25) 7 (9) – 58 (73) 23 (29) 15 (19) 1 (1)
Neutropaenia 46 (58) 18 (23) 14 (18) 1 (1) 55 (67) 13 (16) 25 (32) 3 (4)
Fatigue 60 (76) 25 (32) 9 (11) – 60 (76) 36 (46) 4 (5) –
Peripheral neuropathy 43 (54) 12 (15) 3 (4) – 51 (64.5) 22 (28) 8 (10) –
Nausea/vomiting 37 (47) 8 (10) 1 (1) – 30 (38) 12 (15) 2 (2.5) –
Alopecia 35 (44) 24 (30) / / 32 (40.5) 21 (27) / /
Myalgia/arthralgia 33 (42) 11 (14) 1 (1) – 33 (42) 9 (11) – –
Dyspnoea 14 (18) 4 (5) – – 15 (19) 1 (1) 1 (1) –
Fever 14 (18) 2 (2.5) – – 14 (18) – 1 (1) –
Hepatotoxicity 14 (18) 5 (6) 2 (2.5) – 16 (20) 1 (1) 1 (1) –
Infection 16 (20) 8 (10) 2 (2.5) 1 (1) 8 (10)° 3 (4) – –
Diarrhoea 11 (14) 3 (4) 4 (5) – 15 (19)° 5 (6) – –
Renal toxicity 2 (2.5)° – 1 (1) – 4 (6) 1 (1) – –
Febrile neutropenia 1 (1) / 1 (1) – 2 (2.5) / 2 (2.5) –
CTCAE Common Terminology Criteria for Adverse Events, / corresponding grade does not exist for this adverse event
°Grade 5 (n = 1)
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8, and 15 on a 28-day schedule [21]. Fifty-eight per cent of
those patients had treatment-related toxicities at grade 3
or above, with 30% hospitalised as a consequence. This
study was conducted in patients who exhibited a higher
incidence of markers of vulnerability at baseline geriatric
assessment than in the EFFECT population. This disparity
might in part explain the higher incidence of toxicity ob-
served in the former study when compared with the 100
mg/m2 arm of EFFECT. This further underlines the im-
portance of specifically studying optimal scheduling and
dosing in older, vulnerable patient populations.
Reported outcomes in EFFECT were consistent with
the first-line single-agent chemotherapy data in older
breast cancer patients [22–24]. One of the limitations of
this study is that it did not compare the performance of
weekly nab-paclitaxel with conventional taxanes, such as
solvent-based paclitaxel, which may be seen as the ideal
comparator. Two studies have prospectively evaluated
paclitaxel 80 mg/m2 weekly on days 1, 8, and 15 on a
28-day cycle as the first-line therapy in small groups of
older breast cancer patients [19, 20] and found it to be
active. However, there were also some significant issues
of safety, with one study reporting premature treatment
discontinuation in 32% of patients due to fatigue [23]
and the other observing toxicity-related treatment inter-
ruptions in 15% of patients (5 out of 7 events were due
to cardiac toxicity, including two deaths), and grade 2/3
sensory neurotoxicity in 33% of patients [24].
To our knowledge, this is the first prospective trial
evaluating nab-paclitaxel in a numerically robust older
population that specifically aims to identify the optimal
dose for a population known to be at potentially higher
risk of treatment-related toxicity. The inclusion of geri-
atric assessment and the identification of an elderly-
related endpoint which included functional decline rep-
resent additional strengths of the study. EFS as an end-
point is in line with recommendations generated by the
European Organisation for Research and Treatment of
Cancer (EORTC) [25], which has advocated for alterna-
tive endpoints, such as QoL, toxicity, and functional in-
dependence to be considered as a way of improving the
clinical design. The findings of EFFECT improve the evi-
dence base for treating older adults with cancer, which
is an area of unmet need identified by the American So-
ciety of Clinical Oncology [26].
Conclusions
Weekly taxanes are a suitable treatment option for
older patients with MBC. Whilst solvent-based pacli-
taxel and solvent-based docetaxel are established op-
tions, the EFFECT trial has evaluated a role of weekly
nab-paclitaxel in this selected population, identifying
100 mg/m2 on days 1, 8, and 15 on a 28-day cycle as
an effective and well-tolerated dose.
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